dc.date.accessioned |
2021-06-08T09:12:04Z |
|
dc.date.available |
2021-06-08T09:12:04Z |
|
dc.date.issued |
2020 |
|
dc.identifier.issn |
0021-9541 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12619/96192 |
|
dc.description |
This study was funded by grant at the Uludag University [project no: BUAP(T)-2015/1]. The authors would like to thank Dr. Gokhan Dikmen at the Eskisehir Osmangazi University (Central Research Laboratory, Application, and Research Center) for his helpful advice on various technical issues. |
|
dc.description |
Bu yayının lisans anlaşması koşulları tam metin açık erişimine izin vermemektedir. |
|
dc.description.abstract |
Herein, we investigated efflux pumps-mediated talazoparib-resistance in the treatment of triple-negative breast cancer (TNBC). Furthermore, we produced a novel talazoparib-solid lipid nanoparticles (SLNs) and then explored in vitro therapeutic efficacy of talazoparib-SLNs to overcome talazoparib-resistance in TNBC cells. Talazoparib-SLNs formulation was produced and then characterized. Calcein and Rho-123 were used to analyze the functional activity of drug efflux pumps in these cells. Additionally, RT-PCR, western blot and immunofluorescence analysis were used to detect the messenger RNA, and protein expression level, and cellular localization of the multidrug resistance (MDR1), breast cancer resistance protein (BCRP), and MRP1. We found that talazoparib efflux was mediated by BCRP and MRP1 pumps in TNBC cells. Talazoparib-SLNs could significantly enhance therapeutic efficacy of talazoparib. Furthermore, talazoparib-SLNs were more effective in the suppression of MDR1, BCRP, and MRP1 gene and protein expression levels than talazoparib. Consequently, this study suggests that talazoparib-SLNs formulation represents a promising therapeutic carrier to reverse MDR-mediated resistance in TNBC. |
|
dc.description.sponsorship |
Uludag UniversityUludag University [BUAP(T)-2015/1] |
|
dc.language |
English |
|
dc.language.iso |
eng |
|
dc.publisher |
WILEY |
|
dc.relation.isversionof |
10.1002/jcp.29552 |
|
dc.rights |
info:eu-repo/semantics/closedAccess |
|
dc.subject |
SOLID LIPID NANOPARTICLES |
|
dc.subject |
PARP INHIBITOR TALAZOPARIB |
|
dc.subject |
MULTIPLE-DRUG RESISTANCE |
|
dc.subject |
P-GLYCOPROTEIN |
|
dc.subject |
DNA-REPAIR |
|
dc.subject |
BMN 673 |
|
dc.subject |
OLAPARIB |
|
dc.subject |
CHEMORESISTANCE |
|
dc.subject |
COMBINATION |
|
dc.subject |
INVOLVEMENT |
|
dc.title |
Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer |
|
dc.type |
Article |
|
dc.contributor.authorID |
Egeli, Unal/0000-0001-7904-883X |
|
dc.contributor.authorID |
Tunca, Berrin/0000-0002-1619-6680 |
|
dc.contributor.authorID |
Cecener, Gulsah/0000-0002-3820-424X |
|
dc.contributor.authorID |
guney eskiler, gamze/0000-0002-2088-9914 |
|
dc.identifier.volume |
235 |
|
dc.identifier.startpage |
6230 |
|
dc.identifier.endpage |
6245 |
|
dc.relation.journal |
JOURNAL OF CELLULAR PHYSIOLOGY |
|
dc.identifier.issue |
9 |
|
dc.identifier.doi |
10.1002/jcp.29552 |
|
dc.identifier.eissn |
1097-4652 |
|
dc.contributor.author |
Eskiler, Gamze Guney |
|
dc.contributor.author |
Cecener, Gulsah |
|
dc.contributor.author |
Egeli, Unal |
|
dc.contributor.author |
Tunca, Berrin |
|
dc.relation.publicationcategory |
Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı |
|
dc.identifier.pmıd |
32017076 |
|